| Ytd | 30.58% | |
| 1y | 5.82% |
| Open | 24.00 | Prev Close | 24.00 | Low | 24.00 | High | 24.00 | Mkt Cap | 2.40B |
| Vol | 2.66M | Avg Vol | 4.52M | EPS | -0.28 | P/E | -85.71 | Forward P/E | 52.46 |
| Beta | 1.54 | Short Ratio | 4.59 | Inst. Own | 89.17% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-07 | 50-d Avg | 23.65 | 200-d Avg | 21.78 | 1yr Est | 24.00 |
OS News
Annis Gardner Whiting Capital Advisors LLC increased its stake in shares of OneStream, Inc. (NASDAQ:
AVON, Ohio & OAKLAND, Calif.--(BUSINESS WIRE)--Advanced Polymer Coatings (APC), a global leader in p
Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 4
[url="]Genmab A/S[/url] (Nasdaq: GMAB) today announced new data from two studies evaluating epcorita
New TALVEYÂ (talquetamab-tgvs) plus DARZALEX FASPROÂ (daratumumab and hyaluronidase-fihj) data demon
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evalu
[url="]BeOne Medicines Ltd.[/url] (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company
BOSTON--(BUSINESS WIRE)--WilliamsMarston, a national leader in complex accounting, tax, technology,
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Products Ad
Further positive results from the Phase III SERENA-6 trial showed AstraZeneca's camizestrant plus a
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial
Summit Therapeutics Inc. (NASDAQ: SMMT) today announced positive overall survival (OS) results from
[url="]Pfizer Inc. [/url](NYSE: PFE) today announced detailed progression-free and overall survival
Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or d
[url="]Pfizer Inc. [/url](NYSE: PFE) today announced detailed results from the pivotal Phase 3 TALAP
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evalu
RYBREVANTÂ (amivantamab-vmjw) plus LAZCLUZEÂ (lazertinib) demonstrates prolonged clinical benefit as
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision
AstraZeneca's IMFINZIÂ (durvalumab) in combination with Bacillus Calmette-GuÃrin (BCG) induction and
As CFOs take point on leading enterprise AI strategy, new operating model guides Finance in rebuildi
